teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 57
teleo-codex/entities/health/uspstf.md
Teleo Agents 2d6b80a758
Some checks are pending
Sync Graph Data to teleo-app / sync (push) Waiting to run
Details
vida: extract claims from 2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap 
- Source: inbox/queue/2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap.md
- Domain: health
- Claims: 1, Entities: 1
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
2026-04-13 04:27:12 +00:00

1.6 KiB
Raw Blame History

United States Preventive Services Task Force (USPSTF)

Overview

Independent panel of national experts in prevention and evidence-based medicine that makes recommendations about clinical preventive services. USPSTF A/B recommendations trigger ACA Section 2713 mandatory coverage without cost-sharing for all non-grandfathered insurance plans.

Key Mechanism

USPSTF recommendations are the most powerful single policy lever for mandating coverage of preventive services in the US healthcare system. Grade A/B recommendations automatically trigger mandatory coverage requirements under the Affordable Care Act.

Timeline

  • 2018-09-18 — Published Grade B recommendation for adult obesity covering intensive multicomponent behavioral interventions (≥12 sessions in year 1); reviewed pharmacotherapy but declined to recommend due to insufficient maintenance data; therapeutic-dose GLP-1 agonists not yet available
  • 2024 — Updated children and adolescents obesity recommendation (behavioral-only, did not address adult pharmacotherapy)
  • 2026-04 — Adult obesity topic flagged as 'being updated' on website but redirect points toward cardiovascular prevention rather than GLP-1 pharmacotherapy; no formal petition for GLP-1 review publicly announced

Policy Gap

As of April 2026, the 2018 recommendation remains operative despite substantial clinical evidence base for therapeutic-dose GLP-1 agonists (STEP trials, SURMOUNT trials, SELECT cardiovascular outcomes data) that could support an A/B rating. No formal nomination or petition process for GLP-1 pharmacotherapy review has been initiated.